Ranked by reported Q2 2026 13F market value
Share of total reported institutional value in DMRA held by the largest 10 / 25 filers.
| # | Institution | Shares Held | Market Value | QoQ Change | Ownership % | % of Fund |
|---|---|---|---|---|---|---|
| 1 | FMR LLC | 9.2M | $240.1M | +2.1% | 56.416% | 0.01% |
| 2 | Fairmount Funds Management LLC | 8.7M | $226.6M | 0.0% | 53.238% | 14.98% |
| 3 | Avoro Capital Advisors LLC | 3.8M | $98.4M | 0.0% | 23.115% | 0.88% |
| 4 | Venrock Adviser, LLC | 3.6M | $93.7M | 0.0% | 22.019% | 2.84% |
| 5 | BlackRock, Inc. | 3.2M | $82.2M | +1321.6% | 19.321% | 0.00% |
| 6 | FCPM III SERVICES B.V. | 2.4M | $63.5M | 0.0% | 14.915% | 8.46% |
| 7 | RA CAPITAL MANAGEMENT, L.P. | 2.4M | $62.4M | +0.0% | 14.663% | 0.54% |
| 8 | VIKING GLOBAL INVESTORS LP | 2.3M | $60.1M | 0.0% | 14.121% | 0.17% |
| 9 | Jupiter Topco LLC | 2.3M | $59.3M | — | 13.948% | 0.02% |
| 10 | Remedium Capital Partners, LLC | 2.0M | $53.2M | 0.0% | 12.498% | 11.78% |
| 11 | Commodore Capital LP | 1.9M | $50.4M | 0.0% | 11.848% | 3.00% |
| 12 | JPMORGAN CHASE & CO | 2.1M | $49.8M | — | 12.581% | 0.00% |
| 13 | BRAIDWELL LP | 1.6M | $42.1M | +81.1% | 9.901% | 1.56% |
| 14 | Bellevue Group AG | 1.6M | $42.1M | -29.5% | 9.892% | 0.89% |
| 15 | STATE STREET CORP | 1.5M | $40.2M | +740.3% | 9.443% | 0.00% |
| 16 | a16z Capital Management, L.L.C. | 1.2M | $32.2M | 0.0% | 7.553% | 0.23% |
| 17 | BALYASNY ASSET MANAGEMENT L.P. | 1.2M | $32.0M | -15.1% | 7.510% | 0.04% |
| 18 | PERCEPTIVE ADVISORS LLC | 1.2M | $31.8M | 0.0% | 7.473% | 0.48% |
| 19 | WELLINGTON MANAGEMENT GROUP LLP | 1.1M | $27.5M | 0.0% | 6.465% | 0.00% |
| 20 | Blackstone Inc. | 1.0M | $26.1M | +99.2% | 6.128% | 0.07% |
| 21 | Cormorant Asset Management, LP | 1.0M | $26.0M | -34.4% | 6.110% | 1.33% |
| 22 | GEODE CAPITAL MANAGEMENT, LLC | 965K | $25.1M | +300.4% | 5.899% | 0.00% |
| 23 | Siren, L.L.C. | 900K | $23.4M | 0.0% | 5.499% | 0.47% |
| 24 | UBS Group AG | 840K | $21.9M | +423.8% | 5.134% | 0.00% |
| 25 | Vestal Point Capital, LP | 575K | $15.0M | -4.2% | 3.513% | 0.35% |
denotes a marquee investor (Buffett, Burry, ARK, Tiger Global, Pershing Square, Baupost and other widely-followed managers). “% of Fund” shows how much of that investor’s total 13F portfolio is invested in DMRA — a direct measure of their conviction.
Filings activity in DMRA during Q2 2026, grouped by how each filer changed its position.
Institutions that opened a new DMRA position in Q2 2026
Institutions that fully closed their DMRA position in Q2 2026
8 quarters of 13F filings · Δ columns show change vs prior quarter
| Quarter | Inst. Holders | Δ Holders | Ownership % | Δ Ownership | Total 13F Value | Δ Value |
|---|---|---|---|---|---|---|
| Q2 2026 | 99 | +52% | 199.99% | +0.00 pp | $1.67B | +15% |
| Q1 2026 | 65 | +282% | 199.99% | +29.41 pp | $1.45B | +2211% |
| Q4 2025 | 17 | +42% | 170.58% | +159.92 pp | $63M | +10629% |
| Q3 2025 | 12 | +20% | 10.66% | +2.35 pp | $1M | +30% |
| Q2 2025 | 10 | 17% | 8.31% | 0.62 pp | $0M | +2.1% |
| Q1 2025 | 12 | +9.1% | 8.93% | +0.04 pp | $0M | 33% |
| Q4 2024 | 11 | +10% | 8.89% | +0.84 pp | $1M | 58% |
| Q3 2024 | 10 | — | 8.05% | — | $2M | — |
Source: SEC 13F institutional filings. Ownership % requires market cap data and will show once linked. Δ columns compare to the immediately prior filed quarter.
Institutional ownership and quarterly buying activity across the largest Oncology Biotech peers.
Quick answers to the most common questions about buying DMRA stock.
Based on Q2 2026 13F filings, institutional ownership of Damora Therapeutics, Inc. stands at 200.0%, held across 99 reporting institutions.
FMR LLC is the largest reported institutional holder of DMRA, with approximately 9,232,979 shares worth $0.24B as of Q2 2026.
Yes — 1 widely-followed marquee investor appear among the top 25 institutional holders of DMRA, including VIKING GLOBAL INVESTORS LP.
Our composite Smart Money Score for DMRA is 61 out of 100 (Bullish). It combines net institutional buying activity, ownership shift, marquee investor presence, and holder-count growth.
46 institutions opened new positions in DMRA during Q2 2026, while 13 fully exited. 41 added to existing positions and 8 trimmed.
DMRA institutional ownership rose by 0.00 percentage points quarter-over-quarter, with a net change of +34 holders.
The top 10 institutions account for 62.2% of all reported 13F value in DMRA, and the top 25 account for 91.3%.
Across the largest Oncology Biotech peers, institutional ownership levels are: FTH (54.5%), LONA (184.4%), KYNB (26.9%), CNSY (4.8%), NXTS (3.3%). See the peer comparison table on this page for net buyer activity by company.
All data is sourced from SEC Form 13F filings, which institutional investment managers with at least $100M in assets are required to file each quarter. We process every 13F filing from EDGAR and recompute the aggregates after each cycle. Insider transactions are sourced from Form 4 filings.